Patents by Inventor Olivier Alexis Georges Querolle

Olivier Alexis Georges Querolle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pteridines as FGFR inhibitors
    Patent number: 10272087
    Abstract: The invention relates to new pteridine derivative compounds, of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: April 30, 2019
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Gordon Saxty, Christopher Charles Frederick Hamlett, Valerio Berdini, Christopher William Murray, Patrick René Angibaud, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet
  • CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS
    Publication number: 20190119299
    Abstract: Fused aromatic bicyclic substituted 5-(2-amino-4-pyrimidinyl)-cyanoindoline derivatives (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: June 29, 2017
    Publication date: April 25, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3KB INHIBITORS
    Publication number: 20190062311
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: October 7, 2016
    Publication date: February 28, 2019
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors
    Patent number: 10202387
    Abstract: The present invention relates to heterocyclyl linked imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 12, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey
  • Imidazopyridazine derivatives as PI3KB inhibitors
    Patent number: 10087187
    Abstract: The present invention relates to substituted imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 2, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey
  • Substituted quinoxalines as FGFR kinase inhibitors
    Patent number: 10052320
    Abstract: The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: August 21, 2018
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Steven John Woodhead, Christopher William Murray, Valerio Berdini, Gordon Saxty, Gilbert Ebai Besong, Lieven Meerpoel, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet
  • Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
    Patent number: 10045982
    Abstract: The invention relates to new pyridopyrazine derivative compounds of formula (I-A) or formula (I-B): to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: August 14, 2018
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Valerio Berdini, Gordon Saxty, Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Bruno Roux, Lieven Meerpoel
  • Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
    Patent number: 10004733
    Abstract: The invention relates to new pyridopyrazine derivative compounds of formula (I-A) or formula (I-B): to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 26, 2018
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Valerio Berdini, Gordon Saxty, Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Bruno Roux, Lieven Meerpoel
  • PYRAZOLYL QUINOXALINE KINASE INHIBITORS
    Publication number: 20180127397
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: November 13, 2017
    Publication date: May 10, 2018
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Gordon SAXTY, Christopher William MURRAY, Valerio BERDINI, Gilbert Ebai BESONG, Christopher Charles Frederick HAMLETT, Christopher Norbert JOHNSON, Steven John WOODHEAD, Michael READER, David Charles REES, Laurence Anne MEVELLEC, Patrick René ANGIBAUD, Eddy Jean Edgard FREYNE, Tom Cornelis Hortense GOVAERTS, Johan Erwin Edmond WEERTS, Timothy Pietro Suren PERERA, Ronaldus Arnodus Hendrika Joseph GILISSEN, Berthold WROBLOWSKI, Jean Fernand Armand LACRAMPE, Alexandra PAPANIKOS, Olivier Alexis Georges QUEROLLE, Elisabeth Thérèse Jeanne PASQUIER, Isabelle Noëlle Constance PILATTE, Pascal Ghislain André BONNET, Werner Constant Johan EMBRECHTS, Rhalid AKKARI, Lieven MEERPOEL
  • HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS
    Publication number: 20180057496
    Abstract: The present invention relates to heterocyclyl linked imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: December 18, 2015
    Publication date: March 1, 2018
    Inventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey
  • IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS
    Publication number: 20180002336
    Abstract: The present invention relates to substituted imidazopyridazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: December 18, 2015
    Publication date: January 4, 2018
    Applicant: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Lieven Meerpoel, Sophie Coupa, Virginie Sophie Poncelet, Isabelle Noelle Constance Pilatte, Elisabeth Therese Jeanne Pasquier, Didier Jean-Claude Berthelot, Olivier Alexis Georges Querolle, Christophe Meyer, Patrick Rene Angibaud, Christophe Gabriel Marcel Demestre, Guillaume Jean Maurice Mercey
  • Pyrazolyl quinoxaline kinase inhibitors
    Patent number: 9850228
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: December 26, 2017
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Olivier Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • Compounds
    Patent number: 9737544
    Abstract: The invention relates to new pyridopyrazine and naphthyridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: August 22, 2017
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Patrick René Angibaud, Isabelle Noëlle Constance Pilatte, Olivier Alexis Georges Querolle
  • PTERIDINES AS FGFR INHIBITORS
    Publication number: 20170000796
    Abstract: The invention relates to new pteridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: July 6, 2016
    Publication date: January 5, 2017
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Gordon SAXTY, Christopher Charles Frederick HAMLETT, Valerio BERDINI, Christopher William MURRAY, Patrick René ANGIBAUD, Olivier Alexis Georges QUEROLLE, Virginie Sophie PONCELET
  • Quinazolinone derivatives useful as FGFR kinase modulators
    Patent number: 9493426
    Abstract: The invention relates to new quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: November 15, 2016
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Patrick René Angibaud, Olivier Alexis Georges Querolle, Isabelle Noëlle Constance Pilatte, Lieven Meerpoel, Virginie Sophie Poncelet
  • PYRAZOLYL QUINOXALINE KINASE INHIBITORS
    Publication number: 20160311800
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: April 28, 2016
    Publication date: October 27, 2016
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Gordon SAXTY, Christopher William MURRAY, Valerio BERDINI, Gilbert Ebai BESONG, Christopher Charles Frederick HAMLETT, Christopher Norbert JOHNSON, Steven John WOODHEAD, Michael READER, David Charles REES, Laurence Anne MEVELLEC, Patrick René ANGIBAUD, Eddy Jean Edgard FREYNE, Tom Cornelis Hortense GOVAERTS, Johan Erwin Edmond WEERTS, Timothy Pietro Suren PERERA, Ronaldus Arnodus Hendrika Joseph GILISSEN, Berthold WROBLOWSKI, Jean Fernand Armand LACRAMPE, Alexandra PAPANIKOS, Olivier Alexis Georges QUEROLLE, Elisabeth Thérèse Jeanne PASQUIER, Isabelle Noëlle Constance PILATTE, Pascal Ghislain André BONNET, Werner Constant Johan EMBRECHTS, Rhalid AKKARI, Lieven MEERPOEL
  • Pyrazolyl quinoxaline kinase inhibitors
    Patent number: 9464071
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: October 11, 2016
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Olivier Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
  • Pteridines as FGFR inhibitors
    Patent number: 9447098
    Abstract: The invention relates to new pteridine derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: September 20, 2016
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Gordon Saxty, Christopher Charles Frederick Hamlett, Valerio Berdini, Christopher William Murray, Patrick René Angibaud, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet
  • SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS
    Publication number: 20160235744
    Abstract: The invention relates to new pyridopyrazine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: February 9, 2016
    Publication date: August 18, 2016
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Valerio BERDINI, Gordon SAXTY, Patrick Rene ANGIBAUD, Olivier Alexis Georges QUEROLLE, Virginie Sophie PONCELET, Bruno ROUX, Lieven MEERPOEL
  • SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS
    Publication number: 20160220564
    Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: February 3, 2016
    Publication date: August 4, 2016
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Steven John WOODHEAD, Christopher William MURRAY, Valerio BERDINI, Gordon SAXTY, Gilbert Ebai BESONG, Lieven MEERPOEL, Olivier Alexis Georges QUEROLLE, Virginie Sophie PONCELET